Commitments and contingencies (Details Narrative) - USD ($) |
3 Months Ended | 12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Aug. 27, 2021 |
Jun. 30, 2020 |
Mar. 31, 2020 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Oct. 31, 2022 |
Sep. 30, 2022 |
Aug. 31, 2022 |
Aug. 30, 2022 |
Nov. 04, 2020 |
|
| Law suit filing date | May 28, 2019 | |||||||||
| Description on trial dispute resolution | On November 13, 2019, G Farma filed a Cross-Complaint for declaratory relief and breach of contract relating to the consulting agreement between Mentor and G Farma. The Company filed an answer on December 6, 2019, denying each and every allegation. | |||||||||
| Settlement agreement and mutual release [Member] | G Farma Settlors [Member] | ||||||||||
| Liability for Unpaid Claims and Claims Adjustment Expense Schedule, Discussion | The Settlement Agreement requires the G Farma Settlors to pay the Company an aggregate of $500,000 plus interest, payable monthly as follows: (i) $500 per month for 12 months beginning on September 5, 2021, (ii) $1,000 per month for 12 months beginning September 5, 2022, (iii) $2,000 per month for 12 months beginning September 5, 2023, and (iv) increasing by an additional $1,000 per month on each succeeding September 5th thereafter, until the settlement amount and accrued unpaid interest are paid in full. Interest on the unpaid balance shall initially accrue at the rate of 4.25% per annum, commencing February 25, 2021, compounded monthly, and shall be adjusted on February 25th of each year to equal the Prime Rate as published in the Wall Street Journal plus 1%. | |||||||||
| Liability for unpaid claims and claims adjustment expense, net | $ 500,000 | $ 500,000 | $ 500,000 | $ 500,000 | $ 500,000 | |||||
| Liability for unpaid claims and claims adjustment expense, adjustments | $ 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | ||||||
| Liability for accrued unpaid interest | $ 2,000,000 | $ 2,000,000 | $ 2,000,000 | |||||||
| Promissory notes [Member] | ||||||||||
| Debt instrument, face amount | $ 1,166,570 | |||||||||
| G FarmaLabs Limited [Member] | ||||||||||
| Sale leaseback transaction, net book value | $ 126,703 | $ 495,967 | ||||||||
| Loss contingency receivable, proceeds | $ 27,450 | $ 222,031 | ||||||||
| Other income | $ 3,550 | $ 2,000 | ||||||||
| X | ||||||||||
- Definition Liability for accrued unpaid interest. No definition available.
|
| X | ||||||||||
- Definition Face (par) amount of debt instrument at time of issuance. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid claims. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Sum of adjustments to the estimated reserve for unpaid claims and claims adjustment expense. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Discussion accompanying a schedule reflecting the financial activity during the period in the reserves for unpaid claims and claims adjustment expense. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition States the date the complaint was formally filed in a court of law, in arbitration or mediation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of cash inflow from the collection of receivables related to a loss contingency. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Identifies whether the action is pursued in a court of law, an arbitration or mediation, and whether a decision by the Trier of fact in a nontrial proceeding is binding or nonbinding. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of revenue and income classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The net book value of the asset(s) sold in connection with the sale of the property to another party and lease back to the seller. Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|